The current study also indicates that L. paracasei formula carries no detectable genotoxicity ( Tanzer et al., 2010). In the chromosomal aberration test, 0.3, 0.6, 1.25, 2.5, and 5 mg/ml of Vigiis 101 were incubated with Chinese hamster ovary cells for 3 h (with or without S9) or 20 h (without S9). Neither short-term (3 h) nor continuous (20 h) treatment induced chromosomal alterations that were significantly different from the negative GSK 3 inhibitor control. Therefore, these data indicate that exposure to Vigiis 101 does not result in chromosomal

aberrations in cultured mammalian somatic cells under these test conditions. The micronucleus test was performed to assess the in vivo effect of Vigiis 101 on the number (occurrence) of rodent peripheral-blood

micronucleated reticulocytes. The results can be used to evaluate the potential for genetic mutations or damage to chromosomes or to the mitotic apparatus of erythroblasts as a result of Vigiis 101 treatment. After administration of Vigiis 101, no clinical signs or body weight changes were observed compared to the negative control. The number of micronucleated reticulocytes is increased in the positive control group. Therefore, the test appears to be valid and the results are within the acceptable range. There were no significant differences in the number of micronucleated reticulocytes between the treatment groups and the negative control group. Based on these observations, the results of the micronucleus test of Vigiis 101 can be considered negative. Many Lactobacillus strains check details are used in food fermentation and are typically used in the dairy industry to produce cheese, yogurt

Niclosamide and other fermented milk products ( Schmid et al. 2006). L. paracasei subsp. paracasei NTU 101 have been shown to have various beneficial effects on humans and animals. Hence, we conducted 28-day oral study to evaluate the toxicity of Vigiis 101 given its intended use in food. To evaluate the 28-day oral toxicity of Vigiis 101 in Wistar rats, 80 rats were distributed into four groups: a control group (0 mg/kg), low-dose (300 mg/kg), middle-dose (1500 mg/kg), and a high-dose (5000 mg/kg) group with 10 male and 10 female rats in each group. After 28 days of Vigiis 101 administration, the animals were euthanized. Clinical observations were carried out throughout the study period. Neither abnormalities nor deaths were observed at any dose or in the control group. Some of the hematological and clinical chemistry parameters in the treated rats were different from those in the control group. We concluded, however, that there are no significant abnormalities because these variations were within the normal physiological range of rats. Necropsy showed no toxicologically significantly differences in organ weight. Microscopy examination showed no significant histopathological alterations in the organs examined in either the control or the high-dose group of rats.